Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up
Huan Tao, Nenggang Jiang, Yongqian Jia · 2026
Read Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up by Huan Tao, Nenggang Jiang, Yongqian Jia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594707.txt.
Description
Huan Tao, Nenggang Jiang, and Yongqian Jia follow a stubborn blood disorder held in check for six years by one epigenetic drug. The patient has T-cell large granular lymphocyte leukemia with pure red cell aplasia: the marrow stops making red cells. Standard immune suppression with cyclosporine failed. Their 2026 case turns to chidamide, a histone-targeting drug, first paired with thalidomide. Control came quickly. Thalidomide was later dropped, and chidamide alone kept the remission.
A clonal T-cell population persisted on flow tests the whole time. Remission here means the blood counts behave, not that the clone vanished. The team offers chidamide as a convenient salvage option where no standard exists. One case cannot set policy, but six quiet years argue loudly.
Catalog record
| CREATOR | Huan Tao, Nenggang Jiang, Yongqian Jia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |